

# Neuronetics

## Neuronetics to Report First Quarter 2022 Financial and Operating Results and Host Conference Call

April 28, 2022

MALVERN, Pa., April 28, 2022 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, today announced that it plans to release first quarter 2022 financial and operating results prior to market open on Thursday, May 12th, 2022. The Company will host a conference call to review its results at 8:30 a.m. Eastern Time the same day.

The conference call will be broadcast live in listen-only mode via a webcast on the Company's investor relations website at [ir.neuronetics.com](https://ir.neuronetics.com). To listen to the conference call on your telephone, please dial (877) 472-8990 for United States callers or +1 (629) 228-0778 for international callers and reference confirmation code 3684165, approximately ten minutes prior to start time. The replay will be available on the Company's website for approximately 60 days.

### About Neuronetics

Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience and the largest TMS company in the industry, Neuronetics is redefining patient and physician expectations by designing and developing products that improve the quality of life for people suffering from psychiatric disorders. An FDA-cleared, non-drug, noninvasive treatment for people with depression, Neuronetics' NeuroStar® Advanced Therapy system is today's leading transcranial magnetic stimulation (TMS) treatment for major depressive disorder with over four million treatments delivered. NeuroStar is widely researched and backed by the largest clinical data set of any TMS system for depression, including the world's largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment option that produces extraordinary results. For safety information and indications for use, visit [NeuroStar.com](https://NeuroStar.com).

### Investor Contact:

Mike Vallie or Mark Klausner  
ICR Westwicke  
443-213-0499  
[ir@neuronetics.com](mailto:ir@neuronetics.com)

### Media Contact:

EvolveMKD  
646-517-4220  
[NeuroStar@evolvemkd.com](mailto:NeuroStar@evolvemkd.com)

# Neuronetics

Source: Neuronetics